First Header Logo Second Header Logo

Robert P. Byington

TitleProfessor Emeritus of Public Health Sciences, Winston-Salem - Epidemiology and Prevention
InstitutionWake Forest School of Medicine
DepartmentPublic Health Sciences, Winston-Salem - Epidemiology and Prevention
Address
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R03HL045495     (BYINGTON, ROBERT P)Sep 30, 1990 - May 31, 1992
    NIH/NHLBI
    NATURAL HISTORY OF CORONARY HEART DISEASE
    Role: Principal Investigator
    N01HC095178     Sep 30, 1999 - Sep 30, 2008
    NIH/NHLBI
    PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITU-268995178-268095178
    Role: Co-Principal Investigator
    N01HC95178-26-0-1     (BYINGTON, ROBERT P)Sep 30, 1999 - Mar 31, 2010
    NIH/NHLBI
    ACCORD
    Role: Principal Investigator
    N01HC95178-28-0-1     (BYINGTON, ROBERT P)Sep 30, 1999 - Dec 31, 2011
    NIH/NHLBI
    ACCORD
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC, Fleg JL, Rosenberg Y, Byington RP. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol. 2017 04 01; 2(4):370-380. PMID: 28030716.
      Citations:    
    2. Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC, Chen H. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015 Dec; 66(6):1123-9. PMID: 26459421.
      Citations:    
    3. Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M. Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015 Jan 07; 10(1):29-38. PMID: 25343949.
      Citations:    
    4. Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care. 2014; 37(3):686-93. PMID: 24296848.
      Citations:    
    5. Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care. 2014; 37(3):634-43. PMID: 24170759.
      Citations:    
    6. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 03; 364(9):818-28. PMID: 21366473.
      Citations:    
    7. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010 May; 33(5):983-90. PMID: 20427682.
      Citations:    
    8. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29; 362(17):1563-74. PMID: 20228404.
      Citations:    
    9. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29; 362(17):1575-85. PMID: 20228401.
      Citations:    
    10. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010 Jan 08; 340:b4909. PMID: 20061358.
      Citations:    
    11. Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA. Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. Clin Trials. 2009 Oct; 6(5):416-29. PMID: 19737845.
      Citations:    
    12. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12; 358(24):2545-59. PMID: 18539917.
      Citations:    
    13. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008 May 17; 336(7653):1121-3. PMID: 18480116.
      Citations:    
    14. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 Jan 12; 371(9607):117-25. PMID: 18191683.
      Citations:    
    15. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007 May; 25(5):951-8. PMID: 17414657.
      Citations:    
    16. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC, Grimm RH, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007 Jun 18; 99(12A):21i-33i. PMID: 17599422.
      Citations:    
    17. Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun 18; 99(12A):4i-20i. PMID: 17599424.
      Citations:    
    18. Simons-Morton DG, Genuth S, Byington RP, Gerstein HC, Friedewald WT. The burden of treatment failure in type 2 diabetes: response to Brown et al. Diabetes Care. 2005 Mar; 28(3):761-2. PMID: 15735233.
      Citations:    
    19. Byington RP, Sacks FM. Lessons learned from the prospective pravastatin pooling project. Curr Atheroscler Rep. 2004 Sep; 6(5):366-74. PMID: 15296703.
      Citations:    
    20. Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med. 2004 Jan 12; 164(1):40-4. PMID: 14718320.
      Citations:    
    21. Harper MA, Byington RP, Espeland MA, Naughton M, Meyer R, Lane K. Pregnancy-related death and health care services. Obstet Gynecol. 2003 Aug; 102(2):273-8. PMID: 12907099.
      Citations:    
    22. Byington RP, Furberg CD, Herrington DM, Herd JA, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland CC, Applegate WB. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol. 2002 Oct 01; 22(10):1692-7. PMID: 12377751.
      Citations:    
    23. Mancini GB, Miller ME, Evans GW, Byington R, Furberg CD, Pitt B. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). Am J Cardiol. 2002 Jun 15; 89(12):1414-6. PMID: 12062738.
      Citations:    
    24. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002 May 21; 105(20):2341-6. PMID: 12021218.
      Citations:    
    Byington's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (112)
    Explore
    _
    Co-Authors (9)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _